dentalcorp (DNTL) Stifel Jaws & Paws Conference 2025 summary
Event summary combining transcript, slides, and related documents.
Stifel Jaws & Paws Conference 2025 summary
21 Nov, 2025Business overview and growth strategy
Operates nearly 600 dental practices, the only national platform in Canada, with double-digit growth in locations, revenue, and EBITDA since 2011.
Focuses on acquiring entrepreneurial dentists, with 93% of partners remaining since 2011 and a compensation model aligning interests through equity and performance incentives.
Delivers 4%+ organic growth annually, supported by CAD 25 million+ in acquisitions each year.
General practice dentistry makes up 95%+ of the business, with a shift away from standalone specialty practices to insourcing specialty services into GP locations.
Plans to double the business in five years, with Canadian market growth as the primary driver and potential long-term U.S. expansion.
Operational performance and patient growth
Achieved 4.6% organic growth in Q1, with 2.5% from price, and the remainder from volume and insourcing new services like orthodontics and implants.
Patient visits per year increased from 2.1x to 2.4x post-acquisition due to marketing optimization and clinical training.
Active patient growth is driven by both M&A and improved marketing and recall systems.
Insourcing of orthodontics is present in 330 practices, with plans to expand to 40-50 more by end of 2025.
Some softness in discretionary services like Invisalign due to macroeconomic factors, but category remains additive.
M&A environment and financial outlook
M&A activity slowed in 2023-2024 for integration focus, but 2025 is on track for CAD 25 million+ in acquisitions, with strong pipeline and stable valuations at 7x-7.5x EBITDA.
Canadian dental market is only 7% consolidated, offering significant runway for future acquisitions.
Margin expansion is driven by operating leverage from recent investments in HRIS and ERP systems, targeting 20% margins on an IFRS basis within five years.
Free cash flow conversion exceeds 65% of EBITDA, with most reinvested in M&A; 10% allocated to dividends, and leverage expected to decrease to 3.5x by year-end.
Latest events from dentalcorp
- Arrangement to acquire all shares for CAD 11 each approved, pending court and closing conditions.DNTL
AGM 20253 Feb 2026 - Q2 revenue and EBITDA grew double digits, with CDCP boosting patient volumes and outlook strong.DNTL
Q2 20242 Feb 2026 - Strong M&A-driven growth, high recurring revenue, and positive outlook define the Canadian dental sector.DNTL
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Double-digit growth, margin expansion, and strong cash flow conversion in Q3 2024.DNTL
Q3 202415 Jan 2026 - 2024 revenue up 8.4% to $1.55B, margin at 18.5%, and 2025 outlook strong.DNTL
Q4 202425 Dec 2025 - Q2 revenue rose 8.9% with 9.9% EBITDA growth, margin expansion, and guidance reaffirmed.DNTL
Q2 202523 Nov 2025 - Q1 2025 saw double-digit EBITDA growth, margin expansion, and record free cash flow.DNTL
Q1 202521 Nov 2025 - Revenue and EBITDA rose double digits; company to be acquired by GTCR at a 33% premium.DNTL
Q3 20256 Nov 2025